BONE BIOPSY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Bone Biopsy Market Size and Forecast – 2025 to 2032

The Global Bone Biopsy Market is estimated to be valued at USD 772.6 Million in 2025 and is expected to reach USD 1,177.2 Million by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032. This steady growth is driven by the increasing prevalence of bone-related diseases and advancements in minimally invasive diagnostic technologies, which are enhancing the accuracy and efficiency of bone biopsy procedures worldwide.

Key Takeaways of the Global Bone Biopsy Market:

• Closed (percutaneous) biopsy is expected to lead with 65.1% share in 2025.
• Cancer diagnosis is expected to represent the largest application segment, accounting for 42.2% of the market in 2025, driven by the growing incidence of primary bone cancers and metastatic bone disease worldwide.
• Among products, needle biopsy is projected to lead with a 30.3% share in 2025, as it offers an optimal balance of diagnostic accuracy and procedural simplicity.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 23.2% in 2025.

Market Overview:

Market trends indicate a significant shift towards the integration of advanced imaging techniques such as CT and MRI guidance in bone biopsy procedures, improving precision and patient outcomes. Additionally, rising demand for personalized medicine is propelling the adoption of targeted biopsy methods.

Growth in emerging markets, fueled by expanding healthcare infrastructure and rising awareness about bone health, also supports the market's upward trajectory, making it a dynamic sector poised for continued innovation and expansion. For instance, In October 2024. Pharmed Limited, a leading pharmaceutical company in India, launched the India Bone Health Initiative (IBHI) on World Osteoporosis Day, the initiative aims to address growing concerns over osteoporosis and bone health in India. It focuses on raising awareness, providing patient education, offering Bone Mineral Density (BMD) testing through annual camps, and promoting early detection and prevention of osteoporosis.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Bone Biopsy Market Insights, By Procedure Type - Closed (percutaneous) biopsy contributes the highest share of the market owing to its minimally invasive nature and enhanced patient outcomes

The dominance of closed (percutaneous) biopsy within the global bone biopsy market with an estimated share of 65.1% share in 2025, is primarily driven by its minimally invasive procedure which offers significant advantages over traditional open biopsy techniques. This method involves the insertion of a needle through the skin to collect bone tissue samples, enabling clinicians to diagnose various bone-related conditions without the need for large incisions or extensive surgical intervention. The minimally invasive nature of closed biopsy markedly reduces patient discomfort, procedural risks such as infection and bleeding, and postoperative recovery time, making it highly preferred by both healthcare providers and patients.

Furthermore, advancements in imaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound have improved the precision and accuracy of needle placement during closed biopsies. These improvements enable targeted biopsies with minimal collateral damage to surrounding tissues, which is particularly critical when sampling smaller or difficult-to-access bone lesions. Enhanced imaging guidance also increases diagnostic yield, thereby supporting early and accurate disease detection.

In May 2024, a new peer-reviewed study published in Cureus evaluated the effectiveness of percutaneous core needle biopsy (PCNB) for diagnosing musculoskeletal tumors. Conducted on 152 patients between 2020 and 2023, the research demonstrated a high diagnostic yield of 93.4% and an impressive accuracy rate of 97.9%, with no post-biopsy complications reported.

Bone Biopsy Market Insights, By Application - Cancer diagnosis leads due to the increasing prevalence of bone-related malignancies and the critical need for early and accurate diagnostic procedures

Cancer diagnosis remains the largest and most important application segment in the global bone biopsy market with an estimated share of 42.2% in 2025, chiefly driven by the rising incidence of both primary bone cancers and metastatic bone disease worldwide. Bone biopsy plays an indispensable role in confirming malignancy, determining tumor histology, and guiding personalized treatment strategies. Given the complexity and heterogeneity of cancers involving the skeletal system, obtaining precise tissue samples is essential for effective diagnosis.

The growing burden of metastatic cancers particularly from breast, prostate, lung, and renal origins — underscores the need for bone biopsies in the clinical pathway. These secondary bone tumors often present with ambiguous radiological findings, requiring histopathological confirmation via biopsy to establish the origin and extent of metastasis. Accurate diagnosis is critical for staging disease, selecting targeted therapies, and monitoring treatment response, all of which directly impact patient outcomes.

In June 2020, NeoGenomics, Inc., a leading U.S.-based provider of cancer genetic testing services, launched three new liquid biopsy assays targeting advanced non-small cell lung cancer, pan-cancer applications, and select breast cancers. These blood-based tests, developed in collaboration with Inivata, enable the detection of therapeutic targets and prognostic markers in as little as seven days, offering a crucial alternative when tissue samples are limited or inaccessible.

Bone Biopsy Market Insights, By Product Type - Needle biopsy dominates owing to its efficiency, versatility, and advancements in biopsy instrumentation

Needle biopsy leads the product segmentation of the global bone biopsy market with an estimated share of 30.3% in 2025 because it embodies the ideal balance between diagnostic efficacy and procedural simplicity. This category encompasses a range of instruments including core needle biopsy needles, fine needle aspiration biopsy (FNAB) tools, and biopsy guns—each designed to obtain tissue samples with minimal invasion and maximum accuracy.

One key driver of needle biopsy adoption is its procedural efficiency. Compared with open surgical biopsy, needle biopsy requires less preparation, shorter operation times, and enables quicker patient recovery. These features facilitate its use in diverse clinical settings, including outpatient clinics and interventional radiology suites, expanding accessibility and convenience for patients and clinicians alike.

In August 2022, Mammotome, a global leader in breast care solutions, unveiled the Mammotome DualCore biopsy system, its first dual-stage core biopsy device. Part of the company’s ultrasound-guided breast biopsy portfolio, DualCore features three programmable firing modes, one-handed operation, and an ergonomic design to enhance precision and improve patient comfort during challenging biopsies.

Regional Insights:

To learn more about this report, Request sample copy

North America Bone Biopsy Market Analysis and Trends

North America’s the dominance in the global bone biopsy market with an estimated share of 38.3% in 2025 is driven by a highly developed healthcare ecosystem, advanced technological infrastructure, and strong government support for medical research and innovation. The presence of leading medical device manufacturers and frequent adoption of innovative biopsy techniques contribute significantly to this region’s leadership. Well-established reimbursement policies and robust healthcare spending facilitate widespread access to bone biopsy procedures.

 Additionally, collaborations between research institutions and industry players foster continuous advancements. Notable companies such as Hologic, Inc., DePuy Synthes (a Johnson & Johnson company), and Cook Medical play critical roles by developing cutting-edge bone biopsy instruments and minimally invasive devices, thereby enhancing procedural efficiency and patient outcomes. The U.S. dominates within this region due to consolidated hospital networks and proactive USFDA regulatory approvals that expedite product availability.

Asia Pacific Bone Biopsy Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the bone biopsy market with a share of 23.2% in 2025, fueled by expanding healthcare infrastructure, increasing awareness about bone diseases, and with higher incidences of bone-related ailments. For example, on World Osteoporosis Day, Star Health and Allied Insurance, India’s leading standalone health insurer, launched a nationwide campaign to promote early osteoporosis detection, especially among women. The initiative includes free bone scans across 46 cities and wellness camps offering nutritional guidance and expert consultations to encourage preventive care. Emerging economies like China and India are experiencing rapid modernization of their medical facilities supported by favorable government initiatives to improve diagnostic and treatment capabilities.

Lower manufacturing costs and a growing number of local medical device manufacturers further accelerate this growth. Additionally, increasing foreign direct investments and strategic partnerships between multinational corporations and regional companies enhance technology transfer and market penetration. Key players like Becton Dickinson, Medtronic, and local companies such as Trivitron Healthcare actively contribute by introducing cost-effective and region-specific biopsy solutions tailored to the diverse population needs.

Global Bone Biopsy Market Outlook for Key Countries

U.S. Bone Biopsy Market Trends

The U.S. bone biopsy market benefits from significant investments in healthcare infrastructure and research. Major companies like Hologic and DePuy Synthes lead in introducing advanced biopsy tools that promote minimally invasive procedures with improved diagnostic accuracy. Supportive regulatory frameworks and strong insurance coverage make bone biopsy procedures accessible to a broad patient base. Additionally, numerous clinical trials undertaken across the country foster innovation and adoption of next-generation biopsy technologies, reinforcing the country’s leading position.

In May 2023, Argon Medical Devices, a U.S.-based manufacturer specializing in interventional solutions, introduced SuperCore Advantage—a disposable, semi-automatic biopsy device designed to collect larger soft tissue samples for improved diagnostic accuracy. Available in various lengths and gauge sizes, the instrument expands Argon’s biopsy portfolio and offers physicians greater flexibility in clinical procedures.

U.K. Bone Biopsy Market Trends

The U.K. bone biopsy market is experiencing a clear shift toward less invasive and highly precise diagnostic approaches. Needle-based and image-guided biopsies remain the standard of care, as clinicians increasingly favor ultrasound- and CT-guided procedures to improve accuracy and reduce patient discomfort. Alongside this, the rapid rise of liquid biopsy technologies especially those targeting circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) is transforming cancer diagnostics and treatment planning.

On June 16, 2025, King’s College London, a leading academic institution, introduced nanoneedle patches capable of performing painless, real-time tissue sampling, marking a potential breakthrough in replacing conventional biopsy methods.

Germany Bone Biopsy Market Trends

Germany’s bone biopsy market is characterized by a strong network of healthcare institutions and a high standard of medical care delivery, backed by government funding for biomedical research. Leading European players, such as Siemens Healthineers and Fresenius Medical Care, contribute to product innovation and quality improvements in bone biopsy equipment. The country’s emphasis on precision medicine and comprehensive patient care encourages adoption of advanced biopsy techniques, supporting detailed bone disease diagnostics and treatment planning.

In Marh 2025, Labor Dr. Wisplinghoff, a major German medical lab, partnered with Genomic Testing Cooperative to offer cutting-edge DNA and RNA sequencing for tissue and liquid biopsies. The collaboration will enhance precision cancer diagnostics, including molecular insights that support more accurate bone biopsy interpretations.

Japan Bone Biopsy Market Trends

Japan continues to lead in technological innovation within the Asia Pacific region, supported by a sophisticated healthcare framework serving an aging population prone to bone disorders. The country’s stringent quality control and regulatory environment encourage the adoption of highly precise and safe biopsy instruments. Olympus Corporation and Terumo Corporation are prominent contributors, offering specialized bone biopsy devices with advanced imaging and guidance systems. Additionally, government investments in elder care and osteoporosis management programs are driving market growth by expanding the patient base needing diagnostic interventions.

End User Feedback and Unmet Needs

• End users across the global bone biopsy market—including tertiary care hospitals, oncology centers, and diagnostic imaging clinics—consistently emphasize factors shaping their procurement decisions and satisfaction levels. On the positive side, interventional radiologists in high-volume cancer treatment facilities report strong approval of imaging-guided bone biopsy systems. For instance, a European university hospital highlighted improved diagnostic accuracy and reduced patient discomfort after adopting vacuum-assisted biopsy needles integrated with real-time fluoroscopic guidance, resulting in a 20% reduction in repeat procedures. This combination of precision and workflow efficiency has established premium biopsy solutions as critical assets in advanced oncologic diagnostics.
• At the same time, clinicians in mid-tier facilities and public health institutions frequently note operational challenges that limit widespread adoption. A common concern involves restricted access to disposable biopsy kits compatible with older guidance systems, which contributes to diagnostic delays and procedural backlogs. Additionally, users in Southeast Asia and Latin America point out that procurement costs, limited customization, and gaps in technical support constrain broader use of advanced biopsy platforms. These unmet needs—including affordability constraints, lack of modular configurations, and insufficient training—create clear opportunities for manufacturers and policymakers. Expanding tiered pricing models, offering localized support services, and developing adaptable product lines could strengthen customer retention, inspire innovation, and accelerate market penetration across a wider range of care settings.

Market Players, Key Developments, and Competitive Intelligence:

To learn more about this report, Request sample copy

Key Developments:

• In April 2025, Predicta Biosciences, a precision oncology company based in Massachusetts, U.S launched its first Laboratory Developed Test (LDT), GenoPredicta, designed for bone marrow and blood samples. Conducted in a clinical laboratory improvement amendments (CLIA)-approved lab, the test uses advanced genomic profiling to diagnose and guide treatment decisions in multiple myeloma, the second most common blood cancer. Focused on innovative diagnostics for blood cancers and autoimmune diseases.
• In January 2025, Laredo Medical Center, a leading healthcare provider in Texas, U.S launched a new USD 2 million Women’s Imaging Center at its North campus. The facility will offer advanced mammograms, biopsies, and diagnostic services to improve early breast cancer detection. With only 45 percent of local women receiving annual mammograms, the center aims to expand access and reduce backlogs. CEO Mr. Jorge Leal emphasized the hospital’s commitment to prevention and meeting the community’s growing healthcare needs.
• In November 2024, The NIHR Oxford Health Biomedical Research Centre, which supports early-phase medical research in Oxford, introduced bone marrow biopsy services to enhance its trial capabilities. The new procedure was first used in the BIO-004 study, a UKRI-MRC-funded project examining immune responses to repeated malaria infections.
• In April 2024, Scopio Labs, a leader in AI-powered digital morphology, has received USFDA De Novo clearance for its Full-Field Bone Marrow Aspirate (FF-BMA) Application, marking a significant step toward fully digital bone biopsy analysis. This approval introduces a new category for digital hematopathology, enhancing bone marrow aspirate (BMA) diagnostics through AI-powered decision support and high-resolution imaging. By enabling remote review of bone marrow smears, it reduces turnaround time, improves collaboration, and bolsters diagnostic confidence, similar to innovations seen in the bone biopsy market.

Top Strategies Followed by the global bone biopsy market

• Established market leaders such as BD (Becton, Dickinson and Company) and Argon Medical Devices primarily invest heavily in research and development (R&D) to innovate and introduce high-performance bone biopsy devices that meet the evolving needs of clinicians and patients. For example, BD’s Jamshidi bone biopsy systems are known for their precision and ergonomic designs, which have become a benchmark in the market.
  • These companies focus on enhancing the precision, safety, and ease of use of their products through advanced materials and the integration of technologies such as real-time imaging compatibility and navigation systems. For example, in November 2022, Royal Philips N.V., a global health technology leader, showcased new AI-powered diagnostic systems and workflow solutions at the Radiological Society of North America (RSNA) 2022. These tools help reduce complexity, ease staff shortages, and improve imaging quality

• Mid-level players, such as Stryker Corporation and Cardinal Health, compete by offering cost-effective bone biopsy solutions that strike a balance between quality and affordability, aiming to attract price-sensitive healthcare providers without compromising clinical efficacy.
  • For example, Stryker’s TriGen biopsy instruments provide dependable performance at more accessible price points, gaining strong traction in developing regions across Asia Pacific and Latin America. These companies often position themselves as reliable alternatives to premium offerings, making them particularly appealing in emerging markets where budget constraints are more pronounced.

• Small-scale players differentiate themselves by carving out specialized niches within the bone biopsy market. They emphasize unique or innovative product features that address specific clinical needs or hard-to-reach patient populations, such as minimally invasive techniques or customizable devices. For example, ARGON Medical Devices, a mid-sized innovator, has developed specialized bone biopsy systems like the TLAB Transvenous Liver Biopsy System that cater to minimally invasive procedures and hard-to-access anatomical sites.
  • Similarly, SOMATEX Medical Technologies, known for its precision-engineered biopsy and localization tools, has focused on niche applications such as small bone and vertebral biopsies using advanced coaxial needle systems. Companies like Izi Medical Products leverage proprietary markers and minimally invasive devices to improve targeting accuracy and patient comfort.

Market Report Scope

Bone Biopsy Market Dynamics

To learn more about this report, Request sample copy

Bone Biopsy Market Driver - Rising Prevalence of Bone Cancer and Hematologic Malignancies

The increasing incidence of bone cancers and hematologic malignancies worldwide is significantly driving the demand for advanced bone biopsy procedures, as these conditions often require precise diagnosis through tissue sampling. Bone cancer, including primary tumors such as osteosarcoma and metastatic lesions originating from other cancers, as well as hematologic malignancies like multiple myeloma and lymphoma affecting the bone marrow, necessitate accurate and timely detection to guide effective treatment strategies. As awareness of early diagnosis becomes more widespread, healthcare providers are increasingly relying on bone biopsy techniques to obtain critical pathological information. Additionally, the rising global burden of these malignancies is coupled with advancements in biopsy technology, enabling minimally invasive, safer, and more accurate sampling methods.

In January 2025, the American Cancer Society projects about 3,770 new cases of primary bone and joint cancers in the U.S. in 2025, leading to 2,190 deaths. Although primary bone cancers account for less than 1% of all cancers, they remain a serious threat, especially to children and young adults. Osteosarcoma is the most common type in youth, while chondrosarcoma is more frequent in adults.

Bone Biopsy Market Opportunity - Integration of Robotic-Assisted Biopsy Systems

The integration of robotic-assisted biopsy systems presents a significant opportunity to transform the global bone biopsy market by enhancing precision, safety, and patient outcomes. These advanced systems offer superior accuracy in needle placement during bone biopsy procedures, minimizing human error and reducing the risk of complications such as tissue damage or infection. With increasing adoption of minimally invasive techniques across healthcare settings, robotic-assisted technology can address limitations associated with traditional manual biopsy methods, especially in complex anatomical regions. Additionally, the technology supports real-time imaging integration, enabling clinicians to navigate challenging bone structures with greater confidence and efficiency, potentially shortening procedure times and improving diagnostic yield. The growing emphasis on personalized medicine also fuels demand for more precise biopsy techniques, where robotic assistance can ensure the accurate collection of samples critical for tailored therapeutic strategies. Furthermore, ongoing technological advancements and declining costs of robotic platforms are expected to drive broader accessibility across emerging and developed markets.

In February 2022, on World Osteoporosis Day, Belgium-based biopharmaceutical company UCB, licensed its BoneBot AI to Austria’s ImageBiopsy Lab to detect hidden vertebral fractures on CT scans, improving early osteoporosis diagnosis. Integrated into the ZOO MSK platform, the technology will launch globally by 2023. By identifying fractures sooner, it supports timely bone biopsies to confirm bone health issues and guide treatment.

Market Segmentation

•  Procedure Type Insights (Revenue, USD Mn, 2020 - 2032)
• • Closed (Percutaneous) Biopsy
  • Open Biopsy
•  Application Insights (Revenue, USD Mn, 2020 - 2032)
• • Cancer Diagnosis
    • Primary Bone Tumors
    • Metastatic Bone Disease
  • Bone Infection Diagnosis
    • Osteomyelitis
    • Septic Arthritis-related Bone Infections
  • Metabolic Bone Disorders
    • Osteoporosis (Diagnostic Confirmation)
    • Paget Disease of Bone
    • Renal Osteodystrophy
  • Genetic Disorders
  • Others (Bone Trauma Assessment, etc.)
•  Product Type Insights (Revenue, USD Mn, 2020 - 2032)
• • Needle Biopsy
    • Fine Needle Aspiration Biopsy (FNAB)
    • Core Needle Biopsy
  • Bone Biopsy Kits
    • Pre-packaged Kits
    • Customized Kits
  • Biopsy Guns
    • Semi-automatic biopsy guns
    • Fully automatic biopsy guns
  • Surgical Biopsy
    • Excisional Biopsy
    • Incisional Biopsy
  • Other Instruments & Accessories
•  Guidance Technology Insights (Revenue, USD Mn, 2020 - 2032)
• • Ultrasound-Guided Biopsy
  • CT-Guided Biopsy
    • Conventional CT
    • Cone-beam CT
  • MRI-Guided Biopsy
  • Fluoroscopy or X-ray Guided Biopsy
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
• • Hospitals
  • Diagnostic Laboratories
  • Specialty Clinics
  • Ambulatory surgical centers
  • Others (Academic & Research Institutes, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • BD (Becton, Dickinson and Company)
  • Medtronic
  • Abbott Laboratories
  • Stryker Corporation
  • Olympus Corporation
  • Hologic, Inc.
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • GE Healthcare
  • Philips Healthcare
  • Canon Medical Systems
  • Boston Scientific Corporation
  • Merit Medical Systems
  • Fujifilm Holdings Corporation
  • Karl Storz GmbH & Co. KG

Sources

Primary Research Interviews

• Practicing Oncologists
• Orthopedic Surgeons
• Radiologists
• Pathologists
• Hospital Procurement Managers
• Medical Device Regulatory Experts
• Senior Executives from Biopsy Device Manufacturers
• Clinical Laboratory Directors

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• Centers for Medicare & Medicaid Services (CMS)
• National Institutes of Health (NIH)
• European Medicines Agency (EMA)
• Organisation for Economic Co-operation and Development (OECD) Health Statistics
• Centers for Disease Control and Prevention (CDC)
• National Health Service (NHS) Digital
• Australian Institute of Health and Welfare (AIHW)
• Health Canada
• Japan Ministry of Health, Labour and Welfare (MHLW)

Trade Publications

• Medical Device and Diagnostic Industry (MD+DI)
• Diagnostic and Interventional Radiology News
• DOTmed HealthCare Business News
• Medical Device Network
• Imaging Technology News (ITN)
• MedTech Insight

Academic Journals

• The Journal of Bone and Mineral Research
• Journal of Clinical Oncology
• European Journal of Radiology
• Skeletal Radiology
• Bone
• Journal of Orthopaedic Research
• Radiology
• American Journal of Roentgenology
• The Lancet Oncology
• New England Journal of Medicine
• Journal of Clinical Pathology

Reputable Newspapers

• The New York Times Health Section
• The Guardian Health
• The Washington Post Health & Science
• Financial Times Healthcare
• The Wall Street Journal Health

Industry Associations

• International Society for Clinical Densitometry (ISCD)
• Radiological Society of North America (RSNA)
• American Academy of Orthopaedic Surgeons (AAOS)
• European Society of Radiology (ESR)
• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• American Association for Clinical Chemistry (AACC)
• National Comprehensive Cancer Network (NCCN)

Public Domain Resources

• PubMed
• U.S. National Library of Medicine

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years